While the study identifies ADORA2A as a key target through molecular docking and pharmacological validation, the specific mechanism by which parthenolide modulates ADORA2A signaling remains unclear. Understanding whether parthenolide acts as an agonist, antagonist, or allosteric modulator is critical for therapeutic development.
Gap type: unexplained_observation
Source paper: Parthenolide inhibits methamphetamine-induced depressive-like behavior by targeting ADORA2A. (2026, Phytomedicine : international journal of phytotherapy and phytopharmacology, PMID:41795299)
The scaffold alters receptor signaling efficacy without strong orthosteric affinity by modifying redox-sensitive lipid nanodomains.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Adenosine Accumulation Metabolic Stress or Hypoxia"]
B["ADORA2A Engagement Gi-coupled Anti-inflammatory Receptor"]
C["cAMP Suppression PKA Activity Reduction"]
D["Microglial Activation Threshold Raised Pro-inflammatory Mediator Release Reduced"]
E["Neuroprotection Reduced Glutamate Toxicity and Oxidative Stress"]
F["ADORA2A Blockade Pro-inflammatory Activation Restored"]
A --> B
B --> C
C --> D
D --> E
F -.->|"counteracts"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for ADORA2A from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations5 with PMIDValidation: 0%6 supporting / 1 opposing
✓For(6)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
MECH 5CLIN 2GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Coupling-specific assays could explain downstream …
Supporting
MECH
-
-
-
-
-
-
A(2A) Adenosine Receptor: A Possible Therapeutic T…
This mechanism is currently underconstrained and easy to overfit post hoc.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Hypothesis 1: Parthenolide does not directly agonize or antagonize ADORA2A; instead it lowers inflammatory adenosine tone in corticostriatal circuits by suppressing NF-kB-driven ectonucleotidase and cytokine programs in astrocytes and microglia. Less extracellular adenosine would reduce tonic ADORA2A signaling and favor D2-linked antidepressant network states. Test: adenosine microdialysis, CD39/CD73 expression, and ADORA2A-cAMP readouts after parthenolide.
Hypothesis 2: Parthenolide covalently perturbs upstream adenosine transport or metabolism, for example ENT1/ENT2 trafficking or adenosine
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Hypothesis 1 has the best systems logic, but it is one step removed from the phrase "specifically modulate ADORA2A signaling." Reduced inflammation can improve mood behavior without ADORA2A being the decisive node, so the claim needs pharmacologic rescue with selective ADORA2A agonists/antagonists.
Hypothesis 2 is attractive because it could generate specificity upstream of the receptor, but there is a major promiscuity risk. Parthenolide is an electrophilic sesquiterpene lactone and may alkylate many proteins; any apparent effect on transport or metabolism must survive chemoproteomic selecti
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
The translation path should start with target-validation rather than medicinal chemistry. Use behavioral and molecular assays in stress paradigms with ADORA2A antagonists, agonists, and genetic loss-of-function to determine whether parthenolide's antidepressant signal collapses when A2A signaling is fixed experimentally.
If the signal truly routes through ADORA2A, the indirect extracellular-adenosine model is the most developable because it suggests measurable biomarkers: adenosine tone, phospho-CREB, DARPP-32 state, and astrocyte/microglial inflammatory markers. Direct receptor chemistry is
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF striatal neurons or striatum-derived cell lines are treated with parthenolide (1–10 μM for 30–60 min), THEN ADORA2A G-protein coupling efficiency will change by >25% compared to vehicle control as measured by BRET-based Gαs recruitment or GTPγS binding assay.
pendingconf: 0.35
Expected outcome: Significant shift in ADORA2A coupling efficiency (>25% change in either direction)
Falsified by: ADORA2A G-protein coupling remains within ±15% of baseline despite parthenolide treatment, indicating no measurable effect on receptor coupling
Method: Striatal neuron cultures or CHO/HEK293 cells engineered to express ADORA2A-eYFP; treatment with parthenolide followed by BRET assay measuring Gαs recruitment or radioactive GTPγS binding
IF lipid raft integrity is pharmacologically disrupted with methyl-β-cyclodextrin (MβCD, 5 mM for 30 min) prior to parthenolide treatment, THEN the parthenolide-induced change in ADORA2A coupling efficiency will be abolished or reduced by >50% compared to parthenolide alone.
pendingconf: 0.28
Expected outcome: MβCD pretreatment attenuates parthenolide's effect on ADORA2A coupling by >50%
Falsified by: MβCD pretreatment does not significantly alter the magnitude or direction of parthenolide's effect on ADORA2A coupling, suggesting membrane microdomains are not the primary mechanism
Method: CHO/HEK293-ADORA2A cells pretreated with MβCD (5 mM, 30 min) to deplete membrane cholesterol and disrupt lipid rafts, followed by parthenolide treatment and BRET-based G-protein coupling measurement